1. Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis
- Author
-
Seiya Takano, Natsuo Tomita, Mayu Kuno, Masanari Niwa, Akira Torii, Taiki Takaoka, Nozomi Kita, Dai Okazaki, Shintaro Yamamoto, Tatsuya Kawai, Chikao Sugie, Yasutaka Ogawa, Kenichi Matsumoto, Kaoru Uchiyama, Shinya Otsuka, Tooru Matsui, Akifumi Miyakawa, Tomoki Mizuno, Masato Iida, Motoki Tanikawa, Mitsuhito Mase, and Akio Hiwatashi
- Subjects
Medicine ,Science - Abstract
Abstract We compared survival outcomes of high-dose concomitant boost radiotherapy (HDCBRT) and conventional dose radiotherapy (CRT) for newly diagnosed glioblastoma (GB). Patients treated with intensity-modulated radiation therapy for newly diagnosed GB were included. In HDCBRT, specific targets received 69, 60, and 51 Gy in 30 fractions, while 60 Gy in 30 fractions was administered with a standard radiotherapy method in CRT. Overall survival (OS) and progression-free survival (PFS) were compared using the Log-rank test, followed by multivariate Cox analysis. The inverse probability of treatment weighting (IPTW) method was also applied to each analysis. Among 102 eligible patients, 45 received HDCBRT and 57 received CRT. With a median follow-up of 16 months, the median survival times of OS and PFS were 21 and 9 months, respectively. No significant differences were observed in OS or PFS in the Kaplan–Meier analyses. In the multivariate analysis, HDCBRT correlated with improved OS (hazard ratio, 0.49; 95% confidence interval, 0.27–0.90; P = 0.021), and this result remained consistent after IPTW adjustments (P = 0.028). Conversely, dose suppression due to the proximity of normal tissues and IMRT field correlated with worse OS and PFS (P = 0.008 and 0.049, respectively). A prospective study with a stricter protocol is warranted to validate the efficacy of HDCBRT for GB.
- Published
- 2024
- Full Text
- View/download PDF